Skip to main content

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025
  • H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025
  • Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – ir@ionis.com760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – media@ionis.com – 760-603-4679

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.16
-2.25 (-0.96%)
AAPL  286.46
+0.27 (0.09%)
AMD  214.95
-0.29 (-0.13%)
BAC  53.68
+0.49 (0.92%)
GOOG  319.41
+3.39 (1.07%)
META  642.29
-4.81 (-0.74%)
MSFT  479.45
-10.55 (-2.15%)
NVDA  180.38
-1.08 (-0.59%)
ORCL  203.52
+2.42 (1.20%)
TSLA  439.18
+9.94 (2.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.